Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner

FDA approves monthly dosing for J&J's Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.
Le Lézard

FDA approves RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...